SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that GB1275, the Company’s oral CD11b modulator for oncology indications, will be featured in a trial-in-progress poster at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, being held November 6-10 in National Harbor, Maryland. The poster will highlight the Company’s ongoing first-in-human Phase 1/2 trial of GB1275 as a monotherapy and in combination with anti-PD-1 therapy in certain advanced solid tumors known to be immuno-oncology resistant, and with standard of care chemotherapy in metastatic pancreatic cancer.
Details for the SITC presentation is as follows:
Title: A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC)
Presenter: Jakob Dupont, MD, Chief Medical Officer, Gossamer Bio
Poster Number: P419
Location: Prince George’s Exhibition Halls AB
Date/Time: November 8, 2019, 12:30-2:00 p.m. and 6:30-8:00 p.m. ET
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.